329 related articles for article (PubMed ID: 34373202)
1. The kynurenine pathway in chronic diseases: a compensatory mechanism or a driving force?
Joisten N; Ruas JL; Braidy N; Guillemin GJ; Zimmer P
Trends Mol Med; 2021 Oct; 27(10):946-954. PubMed ID: 34373202
[TBL] [Abstract][Full Text] [Related]
2. Hypothesis kynurenic and quinolinic acids: The main players of the kynurenine pathway and opponents in inflammatory disease.
Badawy AA
Med Hypotheses; 2018 Sep; 118():129-138. PubMed ID: 30037600
[TBL] [Abstract][Full Text] [Related]
3. Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Mohamadkhani A; Klegeris A; McElhinney A; Mafi Z; Hajiesmaeili M; Sayehmiri F
Front Immunol; 2022; 13():1013784. PubMed ID: 36426364
[TBL] [Abstract][Full Text] [Related]
4. A review of chromatographic methods for bioactive tryptophan metabolites, kynurenine, kynurenic acid, quinolinic acid, and others, in biological fluids.
Fukushima T; Umino M; Sakamoto T; Onozato M
Biomed Chromatogr; 2022 May; 36(5):e5308. PubMed ID: 34978092
[TBL] [Abstract][Full Text] [Related]
5. Tryptophan, kynurenine, and kynurenine metabolites: Relationship to lifetime aggression and inflammatory markers in human subjects.
Coccaro EF; Lee R; Fanning JR; Fuchs D; Goiny M; Erhardt S; Christensen K; Brundin L; Coussons-Read M
Psychoneuroendocrinology; 2016 Sep; 71():189-96. PubMed ID: 27318828
[TBL] [Abstract][Full Text] [Related]
6. Involvement of the kynurenine pathway in human glioma pathophysiology.
Adams S; Teo C; McDonald KL; Zinger A; Bustamante S; Lim CK; Sundaram G; Braidy N; Brew BJ; Guillemin GJ
PLoS One; 2014; 9(11):e112945. PubMed ID: 25415278
[TBL] [Abstract][Full Text] [Related]
7. Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Anderson EW; Jin Y; Shih A; Arazi A; Goodwin S; Roeser J; Furie RA; Aranow C; Volpe B; Diamond B; Mackay M
Lupus Sci Med; 2022 Nov; 9(1):. PubMed ID: 36384965
[TBL] [Abstract][Full Text] [Related]
8. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
[TBL] [Abstract][Full Text] [Related]
9. Influence of periodontal inflammation on tryptophan-kynurenine metabolism: a cross-sectional study.
Kurgan Ş; Önder C; Balcı N; Akdoğan N; Altıngöz SM; Serdar MA; Günhan M
Clin Oral Investig; 2022 Sep; 26(9):5721-5732. PubMed ID: 35588020
[TBL] [Abstract][Full Text] [Related]
10. Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression.
Haroon E; Welle JR; Woolwine BJ; Goldsmith DR; Baer W; Patel T; Felger JC; Miller AH
Neuropsychopharmacology; 2020 May; 45(6):998-1007. PubMed ID: 31940661
[TBL] [Abstract][Full Text] [Related]
11. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse.
Saito K; Markey SP; Heyes MP
Neuroscience; 1992 Nov; 51(1):25-39. PubMed ID: 1465184
[TBL] [Abstract][Full Text] [Related]
12. The Kynurenine Pathway as a Potential Target for Neuropathic Pain Therapy Design: From Basic Research to Clinical Perspectives.
Ciapała K; Mika J; Rojewska E
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681715
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum levels of kynurenine pathway metabolites in patients with Behçet disease.
Eryavuz Onmaz D; Tezcan D; Abusoglu S; Sivrikaya A; Kuzu M; Yerlikaya FH; Yilmaz S; Unlu A
Amino Acids; 2022 Jun; 54(6):877-887. PubMed ID: 35604497
[TBL] [Abstract][Full Text] [Related]
14. Capillary electrochromatography-mass spectrometry of kynurenine pathway metabolites.
Chawdhury ASMMR; Shamsi SA; Miller A; Liu A
J Chromatogr A; 2021 Aug; 1651():462294. PubMed ID: 34098249
[TBL] [Abstract][Full Text] [Related]
15. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases.
Lovelace MD; Varney B; Sundaram G; Lennon MJ; Lim CK; Jacobs K; Guillemin GJ; Brew BJ
Neuropharmacology; 2017 Jan; 112(Pt B):373-388. PubMed ID: 26995730
[TBL] [Abstract][Full Text] [Related]
16. Kynurenine metabolites predict survival in pulmonary arterial hypertension: A role for IL-6/IL-6Rα.
Cai Z; Tian S; Klein T; Tu L; Geenen LW; Koudstaal T; van den Bosch AE; de Rijke YB; Reiss IKM; Boersma E; van der Ley C; Van Faassen M; Kema I; Duncker DJ; Boomars KA; Tran-Lundmark K; Guignabert C; Merkus D
Sci Rep; 2022 Jul; 12(1):12326. PubMed ID: 35853948
[TBL] [Abstract][Full Text] [Related]
17. Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy.
Ryan KM; Allers KA; McLoughlin DM; Harkin A
Brain Behav Immun; 2020 Jan; 83():153-162. PubMed ID: 31606477
[TBL] [Abstract][Full Text] [Related]
18. Tryptophan, kynurenine pathway, and diabetic ketoacidosis in type 1 diabetes.
Hoffman WH; Whelan SA; Lee N
PLoS One; 2021; 16(7):e0254116. PubMed ID: 34280211
[TBL] [Abstract][Full Text] [Related]
19. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
[TBL] [Abstract][Full Text] [Related]
20. Behavioral activation therapy for depression is associated with a reduction in the concentration of circulating quinolinic acid.
Savitz J; Ford BN; Yeh HW; Akeman E; Cosgrove K; Clausen AN; Martell C; Kirlic N; Santiago J; Teague TK; Irwin MR; Paulus MP; Aupperle RL
Psychol Med; 2022 Oct; 52(13):2500-2509. PubMed ID: 33234171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
